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Kirstine Kobberøe Søgaard*, Tove Ejlertsen and Henrik Carl SchønheyderAbstract
Background: Clostridium difficile ribotype 027 has become increasingly prevalent in European countries. The clinical
picture varies from self-limiting diarrhea to pseudomembranous colitis with toxic megacolon and ultimately death.
Use of antibiotics is the principal risk factor; others include comorbidity, advanced age and hospitalization. However
even with extensive knowledge of risk factors, it remains difficult to define “minimum risk,” as illustrated by the
following case.
Case presentation: An 80-year-old Danish man in good health was hospitalized for a penetrating knee injury. He
received 5 days of intravenous cefuroxime after surgical revision and was discharged with oral cephalexin.
Post-discharge he suffered from abdominal discomfort and was readmitted with ileus 4 days after discharge, i.e.
10 days after initiation of antibiotic treatment. His condition deteriorated, and pseudomembranous colitis was
diagnosed. Due to lack of response to vancomycin and metronidazole, a total colectomy was performed. Stool
cultures were positive for CD 027.
Conclusion: Short-term use of cephalosporins may have induced CD 027 infection, and the patient’s age was the
only identifiable risk factor for the fulminant course. Thus, even short-term prophylactic treatment with
cephalosporins cannot be considered entirely safe.
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The increasing incidence and severity of Clostridium
difficile (CD) infections is becoming a major clinical
concern impacting public health. The clinical picture
varies from self-limiting diarrhea to pseudomembranous
colitis with toxic megacolon and ultimately death. CD is
an important cause of hospital-acquired as well as
healthcare-associated disease [1]; furthermore, the inci-
dence of community-associated disease tends to reach
levels equal to hospital-acquired disease [2]. In Denmark,
colitis caused by CD infection has increased markedly
among hospitalized patients over a 10 year period [3], and
since 2009 when registering of subtypes began, the number* Correspondence: kirstine.soegaard@dadlnet.dk
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reproduction in any medium, provided the orof infections with ribotype 027 has doubled [4]. In a
European laboratory survey of CD patients, the propor-
tion of ribotype 027 was 5% [5].
Previous use of antibiotics is the most important risk
factor for CD infection [6], particularly the use of cepha-
losporins [7] and flouroquinolones [8]. The risk is high-
est during or within the first month after antibiotic use
[9]. Other established risk factors include comorbidity,
advanced age and immunosuppression [5]. CD infection
can also occur among “low-risk” populations (i.e., young
people, people without underlying illness, people not
exposed to hospitals or antimicrobials) [2], but people in
good health are generally not affected by serious CD in-
fection. Those with serious CD infection often have a
high degree of comorbidity and long exposure to anti-
biotics [10]. Only a few case reports indicate that gravel Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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nificant comorbidity [11,12]. To emphasize the risk of
fulminant pseudomembranous colitis (PMC) associated
with CD 027, we report a case in a patient with modest
comorbidity given short-term cephalosporin treatment.
Case presentation
An 80-year-old Danish man was admitted to hospital be-
cause of a 2-day history of increasing abdominal discom-
fort and constipation. Ten days earlier he had been
hospitalized and treated for a penetrating knee injury,
and had received a 5-day course of intravenous cefurox-
ime. Baseline comorbidity consisted of essential hyper-
tension, mild sequelae after a minor stroke, and prostate
cancer without proven dissemination. Previous surgical
procedures were limited to appendectomy for perforated
appendicitis 3 years earlier. The patient’s regular medica-
tions were bicalutamide, solifenacin, tamsulosin, simvas-
tatin, losartan and clopidogrel, medications not known
to be related to Clostridium difficile infection. While
walking in the countryside, he had been hit by a small
piece of metal from an agricultural machine. The object
was removed surgically from the knee joint, and a rup-
tured collateral ligament was resutured. He was treated
prophylactically with IV dicloxacillin 2 g at admission
and IV cefuroxime 1.5 g during operation, followed by
750 mg q.i.d. for 5 days postoperatively. He was dis-
charged on day 6 with oral cephalexin 1 g t.i.d (5 weeks’
treatment was scheduled). At the time of readmission
(day 10), he was constipated and suffered from
increasing abdominal discomfort, but he was clinically
stabile, body temperature 36.9°C, serum C-reactive pro-
tein 296 mg/L (<10 mg/L), and white blood cell countFigure 1 The endoscopic examination revealed an intestinal mucosa
pseudomembranes.10.6 *109/L (<10.0 *109/L). However, his condition dete-
riorated rapidly to severe sepsis with high fever,
hypotension and renal failure, and he was transferred to
the intensive care unit. A CT scan of the abdomen
revealed colitis, and sigmoidoscopy showed PMC affect-
ing the distal colon up to the left colic flexure (Figure 1).
Treatment with oral vancomycin and metronidazole was
commenced, but repeated CT scans showed progression
to the transverse and ascending colon. Four days after
initiation of vancomycin and metronidazole (day 14 after
surgery and initiation of cephalosporin treatment), a
total colectomy was performed that left the patient with
a permanent ileostomy. Stool culture was positive for
CD 027, with genes for toxin A, toxin B and binary
toxin.
Methods
Stool samples were cultured on ChromID C. difficile
agar (bioMérieux, Marcy l’Etoil, France) in an atmos-
phere composed of 86% N2, 7% H2 and 7% CO2 at 37°C
for 48 hours. Isolates of C. difficile were characterized by
PCR ribotyping, toxin gene profiling, and deletion stu-
dies undertaken by the National Reference Laboratory
for Enteropathogenic Bacteria at Statens Serum Institut,
Copenhagen, Denmark.
Discussion
The majority of patients infected with CD 027 will suffer
mild to severe diarrhea, whereas a few cases will proceed
to PMC with toxic megacolon, sepsis and a possible fatal
outcome. Cephalosporin use is associated with an
increased risk of CD infection, and 3rd generation cepha-
losporins are considered to have the highest impact oncovered by adherent yellow-white plaques forming
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secreted into small intestine via the gallbladder [9].
However, a growing body of evidence shows that also 1st
and 2nd generation cephalosporins (i.e. cephalexin and
cefuroxime) increase the risk of CD infection [13-15].
Cefuroxime is, however, by some, considered to be safe
when used prophylactically or therapeutically in ortho-
pedic surgery [16,17]. Characterization of the risk factors
for fulminant manifestation of the disease is sparse. A
prospective study including 1,008 Canadian patients
with CD infection found that age was associated with a
severe outcome when the infection was due to CD 027
[18]. A retrospective cohort study of 2,334 hospitalized
patients with CD colitis in the United States found im-
munosuppression and recent comprehensive surgical
procedures to be common predisposing conditions for
colectomy; yet none of the patients undergoing colec-
tomy had had orthopedic surgery [19]. On this basis, we
cautiously conclude that the short-term use of cephalos-
porins induced CD 027 infection in our patient, and that
his advanced age was the main risk factor for the fulmin-
ant progression.
Conclusion
We present a case of fulminant PMC associated with
CD 027 in an elderly patient with only modest comor-
bidity who received a short course of dicloxacillin, cefur-
oxime, and cephalexin subsequent to a surgical revision
of a knee injury. Apart from advanced age there was no
underlying condition that explained the grave outcome
in this patient. This finding further supports the overall
principal of antimicrobial stewardship, which specifies to
reduce inappropriate and excessive use of prophylactic
cefuroxime and cephalexin.
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